ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

TrialWire’s™ Industry Leading AI-powered Patient Recruitment Platform Delivers Continuous Clinical Trial Referrals over Holiday Season

SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- TrialWire™, the industry’s fastest, advanced AI-powered, algorithm-driven patient recruitment platform, today announced its RapidStart™ and RapidRescue™ solutions are ensuring that biotech-sponsored clinical trials continue enrolling patients without interruption across Thanksgiving and the upcoming holiday season—a period when traditional recruitment often stalls.

As clinical teams prepare for the year-end break, leading sponsors increasingly turn to TrialWire’s™ automated recruitment engine. The platform operates 24/7, pre-qualifying and nurturing trial candidates through intelligent, real-time digital engagement to accelerate enrollment rates and ensure timelines are met regardless of site availability. Recent multi-study data show:

  • Studies using TrialWire’s™ automation report a 30–45% increase in eligible referrals compared to conventional outreach in the weeks around major US holidays.
  • AI-driven pre-screening reduces manual administrative time by up to 70%, letting sites focus on high-value interactions.
  • Platform-triggered SMS engagement delivers a 98% open rate and achieves actionable patient responses within 90 seconds—nearly 60x faster than email or phone outreach—a finding confirmed in 2025 independent surveys.​

“Sponsors see that automated, AI-powered processes not only safeguard enrollment continuity during peak holiday downtime, but deliver better-qualified,motivated ‘trial ready’ referrals—so programs rebound instantly post-holiday,” said Susan Fitzpatrick-Napier, CEO TrialWire™.

As the industry’s fastest AI-powered patient recruitment platform, TrialWire™ can activate within 24 hours and quickly turn around underperforming studies with immediate, compliant recruitment intervention. This cuts timing bottlenecks and ensures recruitment is continually optimized—critical for progressing time-sensitive therapeutics across oncology, rare disease, and high-competition indications.​

By combining predictive analytics, intelligent participant matching, and proactive SMS-based support, TrialWire’s™ end-to-end system maintains participant interest and trust—all while ensuring sites are ready to follow up the moment teams are back online.

Talk to a recruitment expert

About TrialWire™

TrialWire™, the industry’s fastest, advanced AI-powered, algorithm-driven patient recruitment platform, can activate in under 24 hours. TrialWire’s™ solutions including RapidStart™ and RapidRescue™ accelerate enrollment through our award-winning all-in-one platform to quickly reach, engage and pre-screen participants to meet development milestones. Designed for biotech and trial sites the TrialWire™ platform has a track record in accelerating study timelines. Powered by Salesforce Health Cloud and fully HIPAA & GDPR compliant, our system ensures world-class security and data integrity. With locations in San Francisco, Sydney, Singapore, and Paris, TrialWire™ operates globally to deliver rapid recruitment continuity for every client.


Media Contact:
TrialWire PR Team
Team@trial-wire.com
+1 415-951-3228
www.trial-wire.com

Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.69
+3.55 (1.63%)
AAPL  271.49
+5.24 (1.97%)
AMD  203.78
-2.24 (-1.09%)
BAC  51.56
+0.56 (1.10%)
GOOG  299.65
+9.67 (3.33%)
META  594.25
+5.10 (0.87%)
MSFT  472.12
-6.31 (-1.32%)
NVDA  178.88
-1.76 (-0.97%)
ORCL  198.76
-11.93 (-5.66%)
TSLA  391.09
-4.14 (-1.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.